Biosimulytics

Biosimulytics develops AI-driven software for in silico polymorph screening and crystal structure prediction to help pharmaceutical companies reduce CMC and form-related risks from the earliest stages of drug development. By combining quantum physics, machine learning, and high-performance cloud computing, we simulate crystal formats and identify potential solid-form risks before they become costly development issues. 

Our approach follows an incremental, phase-appropriate strategy along the drug development pipeline — from candidate selection to late-stage development — enabling targeted in silico efforts that accelerate timelines while reducing uncertainty. Biotech and pharmaceutical companies use our technology to improve decision-making, de-risk development programs, and increase the likelihood of successful drug launches. 

Supported by the European Innovation Council (EIC), Enterprise Ireland, EIT Digital (28 Digital) and through strategic collaborations with major global companies including Viridien (formerly CGG), we are expanding our impact across the international pharmaceutical industry.